CGI Pharmaceuticals

CGI Pharmaceuticals, founded in 2001, was a development-stage company dedicated to the discovery and development of breakthrough small molecule kinase inhibitors for a broad range of oncology, angiogenesis and autoimmune, allergic, and inflammatory diseases. CGI was acquired by Gilead in 2010 for $120M.